RCUS
Arcus Biosciences, Inc.
NYSE · USHealthcareBiotechnology
$28.17+2.92%
Price as of Jul 20, 2026
RCUS growth
Arcus Biosciences, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- +67.4%
- EBITDA
- +12.5%
- EBIT
- +8.7%
- EPS
- +24.6%
- Free cash flow
- -61.4%
- Operating cash flow
- -62.7%
Forward estimates
- Revenue
- -71.7%
- EBITDA
- +84.4%
- EPS
- -26.9%
Three-year CAGR
- Revenue
- +30.2%
- EBITDA
- -24.5%
- EBIT
- -17.0%
- Net income
- -24.7%
- EPS
- -4.8%
- Free cash flow
- —
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.